Herbal blend shows promise against COVID-19 in small trial

NCT ID NCT05043324

Completed Disease control Sponsor: Nguyen Thi Trieu, MD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 4 trial tested a herbal supplement called AntiCov-220 in 82 people with underlying health conditions, including HIV and cancer. The goal was to see if it could prevent and treat COVID-19 by boosting the immune system and fighting the virus. The study compared the supplement to a placebo, but detailed results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AntiCov-220 (a blend of herbal extracts and vitamins)
What this could lead to: If it works, this could offer a way to prevent and treat COVID-19, especially in people with other health conditions.
What could go wrong: This is a small, completed Phase 4 trial with only 82 participants. The results are not yet widely published, and the herbal mixture's effectiveness is uncertain. Some participants had serious conditions like HIV, so results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS COVID-19 hepatitis B virus infection hepatitis C virus infection HIV infectious disease stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19

Contacts and locations

Locations

Saigon Biopharma Company Limited

Ho Chi Minh City, 700000, Vietnam
Saigon Biopharma LLC

Wilmington, Delaware, 19801-6601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.